

1           **Efficacy of a polyvalent injectable vaccine against *Flavobacterium psychrophilum***  
2                           **administered to rainbow trout (*Oncorhynchus mykiss* L.)**

3  
4           R. Hoare<sup>1\*§</sup>, S-J. Jung<sup>2§</sup>, T.P.H. Ngo<sup>3</sup>, K.L. Bartie<sup>1</sup>, K.D. Thompson<sup>4</sup>, A. Adams<sup>1</sup>

5  
6                           <sup>1</sup>*Institute of Aquaculture, University of Stirling, Stirling, UK*

7                           <sup>2</sup>*Chonnam National University, Yeosu, Republic of Korea*

8           <sup>3</sup>*Aquacultural Biotechnology Division, Biotechnology Center of Ho Chi Minh City, Vietnam*

9                           <sup>4</sup>*Moredun Research Institute, Pentland Science Park, Penicuik, UK*

10  
11  
12           **Running head: Efficacy of a polyvalent injectable vaccine against *Flavobacterium psychrophilum***

13  
14  
15  
16  
17  
18  
19  
20  
21  
22   \* Corresponding author: Dr R. Hoare, Institute of Aquaculture, University of Stirling

23   [rh30@stir.ac.uk](mailto:rh30@stir.ac.uk); § these authors contributed equally to this study

24

25 Keywords: *Flavobacterium psychrophilum*, RTFS, vaccine, rainbow trout, adjuvant

26 **Acknowledgements** This work was supported by the EU project TARGETFISH, Targeted  
27 Disease Prophylaxis in European Fish Farming, under FP7 (grant no. 311993). AquaGen™  
28 supplied the trout eggs used in this study.

29

30

## 31 **Abstract**

32 *Flavobacterium psychrophilum* is one of the most important pathogens affecting cultured  
33 rainbow trout (*O. mykiss*). Recent information from UK salmonid farms showed country-wide  
34 distribution of genetically and serologically divergent clones which has hampered the  
35 development of a vaccine for Rainbow Trout Fry Syndrome. The current study assessed the  
36 efficacy of an injectable polyvalent vaccine containing formalin-inactivated *F. psychrophilum*  
37 in rainbow trout. The vaccine was formulated with an oil adjuvant (Montanide ISA 760VG)  
38 or formalin killed cells alone. Duplicate groups of trout ( $60 \pm 13$  g) were given phosphate  
39 buffered saline or vaccine formulated with Montanide by intraperitoneal (i.p.) injection and  
40 challenged by intramuscular (i.m.) injection with a homologous and a heterologous isolate of  
41 *F. psychrophilum* at 525 degree days post-vaccination (dd pv). Significant protection was  
42 achieved in vaccinated fish ( $p=0.0001$ , RPS 76% homologous, 88% heterologous). Efficacy  
43 of the adjuvanted vaccine was also demonstrated by heterologous challenge at 1155 dd pv  
44 resulting in 100% protection, whereas survival in the un-adjuvanted group was not  
45 significantly different from control fish. Levels of specific antibody at 1155 dd pv, as  
46 measured by ELISA, were significantly higher in the fish vaccinated with adjuvant when  
47 compared with unvaccinated fish.

48

49

## 50 **1 Introduction**

51 Rainbow trout fry syndrome (RTFS), caused by *F. psychrophilum*, is a major cause of  
52 mortality in salmonid aquaculture and other species worldwide (Barnes, 2011). *F.*  
53 *psychrophilum* is a highly heterogeneous pathogen, and as a result, only one commercial  
54 vaccine (ALPHA JECT® IPNV-Flavo, a killed injectable vaccine licensed in Chile) is

55 available to control this problematic disease (Gómez, Méndez, Cascales, & Guijarro, 2014;  
56 Wahli & Madsen, 2018). Treatment is still largely limited to the use of antibiotics, which has  
57 led to increased levels of antibiotic resistance (Henríquez-Núñez, Evrard, Kronvall, &  
58 Avendaño-Herrera, 2012; Verner-Jeffreys & Taylor, 2015), highlighting the urgent need for  
59 preventative measures for control of RTFS. The rainbow trout (*O. mykiss*) industry in the UK  
60 is critically dependent on the continued clinical efficacy of a single antimicrobial agent,  
61 florfenicol (Verner-Jeffreys & Taylor, 2015), highlighting the need for the development of a  
62 cross-protective vaccine. As outbreaks in larger trout (50-500 g) have recently been reported  
63 in the UK (Iglesias, 2017) causing reduced appetite, lesions and requiring treatment with  
64 antibiotics, there is also a need for a vaccine to provide longer term protection i.e. over the  
65 whole production cycle.

66 A previous study in our laboratory characterised *F. psychrophilum* by genotyping and  
67 serotyping a large collection of isolates gathered from clinical outbreaks in rainbow trout,  
68 Atlantic salmon (*Salmo salar*) and coho salmon (*Onchorynchus kisutch*) (Ngo et al., 2017).  
69 The work revealed high heterogeneity in the strains of *F. psychrophilum* and highlighted the  
70 need for such studies to enable selection of vaccine candidates with the potential for  
71 protection of both trout and salmon. The vaccine developed from these studies has been  
72 applied to salmon via injection and trout fry by immersion vaccination, resulting in excellent  
73 levels of protection (Hoare et al., 2017; Hoare, Ngo, Bartie, & Adams, 2017). As immersion  
74 vaccines are currently lacking mucosal adjuvants the protection afforded by this method  
75 would only cover the early life stages. Therefore an adjuvanted vaccine delivered by  
76 intraperitoneal (i.p.) injection, would be the optimal method to vaccinate fish at later stages in  
77 the production cycle. Oil adjuvanted vaccines are known to be strong inducers of local

78 inflammatory reactions followed by a specific systemic immune response (Fredriksen et al.,  
79 2013).

80 The current study was performed to assess the efficacy of a polyvalent, whole cell injectable  
81 vaccine containing formalin-inactivated *F. psychrophilum*, with and without adjuvant  
82 (mineral oil, Montanide™) to induce protective immunity in rainbow trout (60 g) against the  
83 pathogen. Protection against a homologous and a heterologous strain was investigated in trout  
84 at 525 dd and efficacy of the vaccine against a heterologous isolate at 1155 dd (nearly twice  
85 that recommended by most vaccine manufacturers for induction of immunity to bacterial  
86 antigens). Immune responses in vaccinated and unvaccinated trout were investigated pre-  
87 challenge by ELISA and Western blot.

88

## 89 **2 Materials and Methods**

### 90 **2.1 Rainbow trout**

91 Rainbow trout eggs were supplied by AquaGen (Norway) and transported on ice to the  
92 aquarium at the Institute of Aquaculture, University of Stirling. On arrival, the eggs were  
93 subjected to iodophor surface disinfection according to the manufacturer's instructions  
94 (Buffodine, Evans Vanodine, UK). Five replicates of 10 eggs were removed and confirmed to  
95 be *F. psychrophilum*-free using a nested PCR that targets the 16S rRNA gene (Ngo et al.,  
96 2017; Toyama, Kita-Tsukamoto, & Wakabayashi, 1994). The eggs were maintained in flow-  
97 through de-chlorinated tap water at 10°C until hatch, and thereafter maintained in a 100 L  
98 flow-through tank (5 L min<sup>-1</sup>). Fry were fed to satiation daily (Inicio feed, 1.1 mm, BioMar,  
99 UK). All experimental procedures with live fish were carried out in accordance with the UK  
100 Animals (Scientific Procedures) Act, 1986 and associated guidelines (EU Directive  
101 2010/63/EU) and were approved by the Ethics Committee of the University of Stirling.

102

## 103 **2.2 Preparation of formalin inactivated bacteria**

104 Two isolates of *F. psychrophilum* recovered from trout and one recovered from Atlantic  
105 salmon in the UK in 2013 were used to make a formalin killed whole cell vaccine (FKC)  
106 (AVU-1T/13, serotype Fd; AVU-2T/13, serotype Th; and AVU-3S/13, serotype FpT; ) as  
107 described previously (Hoare et al., 2017). The three cultures were mixed in equal parts to  
108 form the whole cell vaccine at a final concentration of  $1 \times 10^9$  colony forming units (CFU)  
109 mL<sup>-1</sup>.

110

## 111 **2.3 Preparation of vaccine formulations and vaccination**

112 The formalin-inactivated vaccine prepared above, was emulsified with Montanide 760VG  
113 (Seppic, France) (Montanide70:FKC30) and stored at 4 °C. Stability of the emulsion was  
114 examined macro and microscopically for a 7 day period following emulsification.

115 Fish (60 g  $\pm$  13) were randomly separated into 100 L flow-through tanks with aeration at  
116 15°C. The experimental design of the vaccination trials is summarised in Table 1. As previous  
117 studies have shown no protection after challenge when adjuvant alone is administered  
118 (Fredriksen et al., 2013), an adjuvant-alone group was excluded from this study. Fish were  
119 anaesthetised with benzocaine (Sigma, 0.004%) and vaccinated by i.p. injection (50  $\mu$ l/fish).  
120 Control groups were injected i.p. with 50  $\mu$ l/fish of sterile phosphate buffered saline (PBS).  
121 Prior to challenge (525 dd and 1155 dd pv) fish were anaesthetised with benzocaine (as  
122 above) and blood was sampled from the caudal vein using a 23 G needle and syringe from  
123 three fish per duplicate group (n= 6) stored overnight at 4°C, centrifuged for 5 min at 3000 x g  
124 for collection of serum, and stored at -20°C until analysis.

125

## 126 **2.4 Experimental infection of vaccinated fish**

127 Dose response studies were conducted to determine the lethal dose 60 % (LD<sub>60</sub>) for each  
128 isolate (data not shown). Challenge was conducted with both a homologous strain (AVU-  
129 2T13; 1.3 x 10<sup>7</sup> colony forming units (CFU/fish) and a heterologous strain of *F.*  
130 *psychrophilum* (AVU-1T/07; 3.6 x 10<sup>7</sup> CFU/fish) at 525 dd pv, and only with a heterologous  
131 strain (AVU-1T/07; 1.7 x 10<sup>7</sup> CFU/fish) at 1155 dd pv. The fish were maintained as above  
132 and monitored for 21 days post infection (dpi). Moribund fish or mortalities were removed  
133 and sampled by streaking head kidney, spleen and any lesions onto Modified Veggietone  
134 (MV) medium [veggitones GMO-free soya peptone (Oxoid, UK), 5g L<sup>-1</sup>; yeast extract  
135 (Oxoid, UK), 0.5 g L<sup>-1</sup>; magnesium sulphate heptahydrate (Fisher chemicals, UK), 0.5 g  
136 L<sup>-1</sup>; anhydrous calcium chloride (BHD), 0.2 g L<sup>-1</sup>; dextrose (Oxoid, UK), 2 g L<sup>-1</sup>; agar  
137 (solid medium; Oxoid, UK), 15 g L<sup>-1</sup>; pH 7.3] to confirm specific mortality. A sub-sample of  
138 colonies recovered was screened with a nested PCR (Ngo et al., 2017; Toyama et al., 1994),  
139 to confirm re-isolation of *F. psychrophilum* from the fish.

140

## 141 **2.5 ELISA for detection of specific IgM in serum**

142 Enzyme-linked immunosorbent assay (ELISA) was used to assess specific IgM titres to *F.*  
143 *psychrophilum* in serum according to (Hoare et al., 2017). The trout *F. psychrophilum* vaccine  
144 isolates were used to coat the ELISA plates (Immulon 4 HBX, UK) at 1 x10<sup>8</sup> CFU/mL in PBS  
145 and incubated overnight at 4°C. The dilution of fish serum used was optimised by first  
146 titrating sera from each group (1:32 to 1:1024). Fish sera samples at the optimised dilution of  
147 1:64 in PBS were added to the wells (100 µl/well) in duplicate and incubated overnight at  
148 4°C. The absorbance was read on a BioTek HT Synergy spectrophotometer at 450 nm.

149

## 150 **2.6 Agglutination assay**

151 Sera collected from each group at 1155 dd pv were serially diluted two-fold in PBS and 20 µl  
152 added to each well of a round bottom plate (Nunc™). A 20 µl sample of the homologous  
153 strain (AVU-2T13, 2 x10<sup>8</sup> CFU/mL, formalin-killed) was then added to each well and the  
154 plates were incubated overnight at room temperature. Agglutination was observed under  
155 100X using an inverted microscope (Olympus CK40). The agglutination titre was calculated  
156 as the reciprocal of the highest dilution of serum showing complete agglutination of the  
157 bacteria.

158

## 159 **2.7 SDS-PAGE and Western blotting**

### 160 **Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)**

161 Suspensions of the *F. psychrophilum* vaccine and challenge strains were aliquoted into 1.5 ml  
162 micro-centrifuge tubes (1 ml of 2 x 10<sup>8</sup> CFU/mL), and centrifuged for 15 min at 3000 × g.  
163 Bacterial pellets were prepared and applied to a 12% polyacrylamide gel (Bio-Rad) gel  
164 according to [7]. Gels were stained with Coomassie Brilliant Blue (Bio-Rad) or subjected to  
165 Western blotting. Bacterial components separated by SDS-PAGE as described above, were  
166 transferred onto nitrocellulose membranes and incubated with serum taken at 1155 dd pv  
167 according to [7].

168

## 169 **2.8 Statistical Analysis**

170 Relative percentage survival (RPS) was calculated at 21 days post-challenge. Kaplan-Meier  
171 survival curves were generated and the log-rank test was used to compare the survival curves  
172 for the vaccinated fish and unvaccinated fish (E.L. Kaplan, 1958; Peto et al., 1977). Where  
173 there was a significant difference in mortality between replicate tanks statistical analysis was



174 run on individual tanks. The relative percent survival (RPS) of this trial was calculated using  
175 the following equation (Amend, 1981):

176

$$\text{RPS} = \left[ 1 - \frac{\text{average \% mortality of vaccinated fish}}{\text{average \% mortality of unvaccinated fish}} \right] \times 100$$

177

178 Specific antibody levels were analysed by one-way ANOVA followed by Welch's test.

179

### 180 **3. Results**

#### 181 **3.1 Vaccine Efficacy**

182 **525 dd pv:** The percentage survival of the sham-vaccinated group administered PBS and  
183 challenged with the homologous strain was 40% and with the heterologous strain was 43%.  
184 The vaccinated group had significantly higher survival compared with the unvaccinated  
185 control group following homologous challenge ( $p = 0.0001$ , Figure 1 a). Following  
186 heterologous challenge there was a significant difference between control tanks so individual  
187 tanks were compared and control tank 2 had significantly higher survival compared with  
188 vaccinated tanks ( $p = 0.0001$ , Figure 1 b). The vaccine formulation containing FKC combined  
189 with Montanide ISA 760VG gave high levels of protection against both the homologous and  
190 the heterologous strains of *F. psychrophilum* (RPS of 76% and 88% respectively).

191 Figure 1. here

192 **1155 dd pv:** Percentage survival in the sham-vaccinated trout injected with PBS was 29% and  
193 trout vaccinated with FKC combined with Montanide ISA 760VG had significantly higher  
194 survival compared with the unvaccinated controls, RPS of 100% ( $p = 0.0001$ , Figure 2). The  
195 vaccine formulation with FKC without adjuvant had a RPS of 25%; survival in this group was

196 not significantly different from the control group. Lesions at the challenge injection site were  
197 evident in all unvaccinated fish, approximately 10% of FKC vaccinated fish and were  
198 completely absent from fish vaccinated with FKC and adjuvant.

199 Figure 2. here

200

### 201 **3.2 Nested PCR for detection of *F. psychrophilum***

202 PCR products specific for *F. psychrophilum* (1080 bp) were detected in moribund and dead  
203 fish sampled during the challenge. Conversely, the eggs tested negative by PCR  
204 (Supplementary Figure 1).

205

### 206 **3.3 Specific antibody response**

207 Levels of specific antibody at 1155 dd pv, as measured by ELISA against both trout vaccine  
208 strains, were significantly higher in the fish vaccinated with adjuvant when compared with  
209 unvaccinated fish (AVU 1T/13  $p = 0.01$ , AVU 2T/13  $p < 0.05$ ) (Figure 3. a, b). Fish  
210 vaccinated with FKC alone had higher antibody levels than those of the control group, but this  
211 was not significant.

212 Figure 3 here

213 The specific IgM response of trout to vaccination was also measured by agglutination at 1155  
214 dd pv against the homologous isolate (AVU-2T/13). The unvaccinated group and the group  
215 vaccinated with FKC alone had low titres of 8, whereas the group vaccinated with FKC and  
216 Montanide exhibited a significantly higher average titre of 144 ( $n= 4$ ,  $p = 0.04$ ) (Table 2).

217

### 218 **3.4 SDS-PAGE and Western blot**

219 Distinct bands ranging from 10-100 kDa were evident in the SDS-PAGE profiles of the *F.*  
220 *psychrophilum* strains used to prepare the polyvalent vaccine (and a heterologous strain AVU-

221 1T/07) following staining of gels with Coomassie (Figure 4a). The banding profiles of the  
222 strains were similar with a slightly lower weight band occurring in the heterologous strain  
223 between 20-25 kDa. In Western blotting, stronger staining was evident when *F.*  
224 *psychrophilum* isolates were screened with serum from the fish vaccinated with FKC and  
225 Montanide (Figure 4b (iii)) compared to that seen with serum of unvaccinated (Figure 4b (i))  
226 or FKC only vaccinated fish (Figure 4b (ii)). A prominent band staining strongly between 20-  
227 25 kDa for all the *F. psychrophilum* strains tested was only observed in the blot using sera  
228 from fish vaccinated with FKC and adjuvant. In addition, a region of higher molecular mass  
229 antigens above 75 kDa were recognised by sera from FKC only and FKC and Montanide  
230 vaccinated fish, with stronger staining observed in fish vaccinated with adjuvant.

231

232 Figure 4 a, b. here

233

#### 234 **4. Discussion**

235 Rainbow Trout Fry Syndrome affects juvenile rainbow trout: however recently outbreaks are  
236 occurring in larger fish (50 g+) in the UK (Iglesias, 2017). Therefore, the development of a  
237 vaccine to provide long term protection is needed. The polyvalent vaccine developed against  
238 *F. psychrophilum* in this study provided significant protection against homologous and  
239 heterologous challenge when administered to rainbow trout by i.p. injection (RPS 76-100%).  
240 The success of many injectable vaccines used in aquaculture has been attributed to the  
241 inclusion of adjuvants (Tafalla, Børgwald, & Dalmo, 2013). Adjuvants are substances which  
242 enhance the immune response to an antigen (Awate, Babiuk, & Mutwiri, 2013) and one of the  
243 most effective adjuvants used in aquaculture is mineral oil (Rømer Villumsen, Koppang, &  
244 Raida, 2015). The present study clearly demonstrated the enhanced efficacy of the vaccine  
245 against *F. psychrophilum* when the bacterin was administered with an oil adjuvant

246 (Montanide™) providing protection with no mortality or development of lesions following  
247 challenge at 1155 dd pv.

248 Previous studies using inactivated *F. psychrophilum* in conjunction with oil adjuvants have  
249 demonstrated protection, usually associated with increased levels of specific IgM in the serum  
250 of vaccinated fish (Fredriksen et al., 2013; Hoare et al., 2017; Högfors, Pullinen, Madetoja, &  
251 Wiklund, 2008; Madetoja et al., 2006). The protection in the current study appears to be at  
252 least partly mediated by specific serum antibodies (IgM) as shown by ELISA, agglutination  
253 and Western blotting. Serum antibodies from fish vaccinated with the polyvalent vaccine  
254 recognised a heterologous strain of *F. psychrophilum* by Western blotting. A significantly  
255 stronger reaction was observed in the Western blot when sera from fish vaccinated with  
256 adjuvant was applied with bands staining between 20-25 kDa not observed in blots incubated  
257 with un-adjuvanted sera. An additional region >75 kDa was recognised by sera from both  
258 groups of vaccinated fish with stronger staining in the adjuvanted group. These two regions  
259 appear to be the targets of specific antibodies following vaccination.

260 Previous studies have identified different molecular weight fractions (18–28, 41–49, and 70–  
261 100 kDa) as immunogenic molecules of *F. psychrophilum* by Western blotting, using  
262 convalescent rainbow trout serum (Crump, Perry, Clouthier, & Kay, 2001; Högfors et al.,  
263 2008; Benjamin R. LaFrentz, Lindstrom, LaPatra, Call, & Cain, 2007). These proteins have  
264 potential to be the basis for a recombinant vaccine to provide cross-protection against *F.*  
265 *psychrophilum*. One such study, using convalescent rainbow trout serum, found an immuno-  
266 reactive proteinase K-resistant band with an apparent molecular mass of 17 kDa (Crump et  
267 al., 2001) and suggested the highly immuno-reactive band is likely to be the predominant  
268 component of the thick slime layer seen on the surface of these bacteria, possibly LPS.  
269 Whereas, the high molecular weight fractions are suggested to be part of the glycocalyx of *F.*

270 *psychrophilum* (Benjamin R. LaFrentz et al., 2007). Further studies are needed to assess the  
271 characteristics of the immunogenic band between 20-25 kDa observed in the present study  
272 with regard to a potential recombinant vaccine target which could be cross-protective. Trials  
273 to date that have assessed the efficacy of fractions to protect trout against laboratory challenge  
274 have shown whole cell formulations to provide greater or equal protection (Aoki, Kondo,  
275 Nakatsuka, Kawai, & Oshima, 2007; Högfors et al., 2008; B R LaFrentz, LaPatra, Jones, &  
276 Cain, 2004; Rahman et al., 2002). Studies such as on the potential of the outer membrane  
277 fraction and membrane vesicle rich supernatant from the stationary phase culture supernatants  
278 of *F. psychrophilum* have been shown to induce protective immunity in rainbow trout and ayu  
279 (*Plecoglossus altivelis*) (Aoki et al., 2007; Rahman et al., 2002), however both were less  
280 effective than whole cell formulations. In the present study, the combination of FKC of three  
281 strains of *F. psychrophilum* and an oil adjuvant induced protection (up to 1155 dd) against a  
282 heterologous strain of *F. psychrophilum* in rainbow trout. Further large-scale studies, are  
283 needed to determine the efficacy of the developed vaccine against a range of heterologous  
284 strains from different geographical regions. In addition, studies on the innate and cellular  
285 immune response could provide more insight into the mechanisms of protection provided by  
286 the adjuvanted vaccine.

287

## 288 **Conclusions**

289 The adjuvanted, polyvalent vaccine tested in this study gave excellent protection in rainbow  
290 trout (RPS of 100 %) against a heterologous strain of *F. psychrophilum*. The protection  
291 correlated with systemic IgM responses as observed by ELISA, agglutination and Western  
292 blotting.

293

294 **Conflict of interest**

295 The authors declare that they have no competing interests.

296

297 **Authors Contribution**

298 Conceived and designed the experiments: RH, SJJ, AA. Developed the vaccine: TPHN, KLB,

299 RH, SJJ, AA. Carried out the vaccination and challenge: RH, SJJ, TPHN. Analysed the data:

300 RH, SJJ. Wrote the paper: RH, SJJ, KT, AA.

301

302 **References**

303 Amend, D. F. (1981). Potency Testing of Fish Vaccines. *Fish Biologics: Serodiagnostics and Vaccines*,  
304 49, 447–454.

305 Aoki, M., Kondo, M., Nakatsuka, Y., Kawai, K., & Oshima, S. I. (2007). Stationary phase culture  
306 supernatant containing membrane vesicles induced immunity to rainbow trout *Oncorhynchus*  
307 *mykiss* fry syndrome. *Vaccine*, 25(3), 561–569. <https://doi.org/10.1016/j.vaccine.2006.07.047>

308 Awate, S., Babiuk, L. A., & Mutwiri, G. (2013). Mechanisms of action of adjuvants. *Frontiers in*  
309 *Immunology*. <https://doi.org/10.3389/fimmu.2013.00114>

310 Barnes, M. E. (2011). A Review of *Flavobacterium Psychrophilum* Biology, Clinical Signs, and  
311 Bacterial Cold Water Disease Prevention and Treat. *The Open Fish Science Journal*.  
312 <https://doi.org/10.2174/1874401X01104010040>

313 Crump, E. M., Perry, M. B., Clouthier, S. C., & Kay, W. W. (2001). Antigenic characterization of the fish  
314 pathogen *Flavobacterium psychrophilum*. *Applied and Environmental Microbiology*.  
315 <https://doi.org/10.1128/AEM.67.2.750-759.2001>

316 E.L. Kaplan, P. M. (1958). Nonparametric Estimation from Incomplete Observations Author ( s ): E . L .  
317 Kaplan and Paul Meier Source : Journal of the American Statistical Association , Vol . 53 , No .  
318 282 ( Jun . , 1958 ) , pp . 457- Published by : American Statistical Association Sta. *American*  
319 *Statistical Association*, 53(282), 457–481. <https://doi.org/10.2307/2281868>

320 Fredriksen, B. N., Olsen, R. H., Furevik, A., Souhoka, R. A., Gauthier, D., & Brudeseth, B. (2013).

321 Efficacy of a divalent and a multivalent water-in-oil formulated vaccine against a highly virulent  
322 strain of *Flavobacterium psychrophilum* after intramuscular challenge of rainbow trout  
323 (*Oncorhynchus mykiss*). *Vaccine*. <https://doi.org/10.1016/j.vaccine.2013.01.016>

324 Gómez, E., Méndez, J., Cascales, D., & Guijarro, J. A. (2014). *Flavobacterium psychrophilum* vaccine  
325 development: A difficult task. *Microbial Biotechnology*. <https://doi.org/10.1111/1751-7915.12099>

326 Henríquez-Núñez, H., Evrard, O., Kronvall, G., & Avendaño-Herrera, R. (2012). Antimicrobial  
327 susceptibility and plasmid profiles of *Flavobacterium psychrophilum* strains isolated in Chile.  
328 *Aquaculture*, 354–355, 38–44. <https://doi.org/10.1016/j.aquaculture.2012.04.034>

329 Hoare, R., Jung, S.-J., Ngo, T. P. H., Bartie, K., Bailey, J., Thompson, K. D., & Adams, A. (2017).  
330 Efficacy and safety of a non-mineral oil adjuvanted injectable vaccine for the protection of  
331 Atlantic salmon (*Salmo salar* L.) against *Flavobacterium psychrophilum*. *Fish and Shellfish*  
332 *Immunology*. <https://doi.org/10.1016/j.fsi.2017.10.005>

333 Hoare, R., Ngo, T. P. H., Bartie, K. L., & Adams, A. (2017). Efficacy of a polyvalent immersion vaccine  
334 against *Flavobacterium psychrophilum* and evaluation of immune response to vaccination in  
335 rainbow trout fry (*Oncorhynchus mykiss* L.). *Veterinary Research*, 48(1).  
336 <https://doi.org/10.1186/s13567-017-0448-z>

337 Högfors, E., Pullinen, K. R., Madetoja, J., & Wiklund, T. (2008). Immunization of rainbow trout,  
338 *Oncorhynchus mykiss* (Walbaum), with a low molecular mass fraction isolated from  
339 *Flavobacterium psychrophilum*. *Journal of Fish Diseases*, 31(12), 899–911.  
340 <https://doi.org/10.1111/j.1365-2761.2008.00956.x>

341 Iglesias, V. (2017). Rainbow trout fry syndrome (RTFS) explained.

342 LaFrentz, B. R., LaPatra, S. E., Jones, G. R., & Cain, K. D. (2004). Protective immunity in rainbow  
343 trout *Oncorhynchus mykiss* following immunization with distinct molecular mass fractions isolated  
344 from *Flavobacterium psychrophilum*. *Dis Aquat Organ*, 59(1), 17–26.  
345 <https://doi.org/10.3354/dao059017>

346 LaFrentz, B. R., Lindstrom, N. M., LaPatra, S. E., Call, D. R., & Cain, K. D. (2007). Electrophoretic and  
347 Western blot analyses of the lipopolysaccharide and glycocalyx of *Flavobacterium*  
348 *psychrophilum*. *Fish and Shellfish Immunology*. <https://doi.org/10.1016/j.fsi.2007.02.005>

349 Madetoja, J., Lönnström, L.-G., Björkblom, C., Uluköy, G., Bylund, G., Syvertsen, C., ... Wiklund, T.

350 (2006). Efficacy of injection vaccines against *Flavobacterium psychrophilum* in rainbow trout,  
351 *Oncorhynchus mykiss* (Walbaum). *Journal of Fish Diseases*, 29(1987), 9–20.  
352 <https://doi.org/10.1111/j.1365-2761.2005.00676.x>

353 Ngo, T. P. H., Bartie, K. L., Thompson, K. D., Verner-Jeffreys, D. W., Hoare, R., & Adams, A. (2017).  
354 Genetic and serological diversity of *Flavobacterium psychrophilum* isolates from salmonids in  
355 United Kingdom. *Veterinary Microbiology*, 201. <https://doi.org/10.1016/j.vetmic.2017.01.032>

356 Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., ... Smith, P. G. (1977).  
357 Design and analysis of randomized clinical trials requiring prolonged observation of each patient.  
358 II. Analysis and examples. *British Journal of Cancer*, 35(1), 1–39.  
359 <https://doi.org/10.1038/bjc.1977.1>

360 Rahman, M. H., Kuroda, A., Dijkstra, J. M., Kiryu, I., Nakanishi, T., & Ototake, M. (2002). The outer  
361 membrane fraction of *Flavobacterium psychrophilum* induces protective immunity in rainbow  
362 trout and ayu. *Fish and Shellfish Immunology*. <https://doi.org/10.1006/fsim.2001.0362>

363 Rømer Villumsen, K., Koppang, E. O., & Raida, M. K. (2015). Adverse and long-term protective effects  
364 following oil-adjuvanted vaccination against *Aeromonas salmonicida* in rainbow trout. *Fish &*  
365 *Shellfish Immunology*, 42(1), 193–203. <https://doi.org/10.1016/j.fsi.2014.09.024>

366 Tafalla, C., Bøgwald, J., & Dalmo, R. A. (2013). Adjuvants and immunostimulants in fish vaccines:  
367 Current knowledge and future perspectives. *Fish and Shellfish Immunology*.  
368 <https://doi.org/10.1016/j.fsi.2013.02.029>

369 Toyama, T., Kita-Tsukamoto, K., & Wakabayashi, H. (1994). Identification of *Cytophaga psychrophila*  
370 by PCR Targeted 16S Ribosomal RNA. *Fish Pathology*, 29(4), 271–275.  
371 <https://doi.org/10.3147/jsfp.29.271>

372 Verner-Jeffreys, D. W., & Taylor, N. J. (2015). *Review of freshwater treatments used in the Scottish*  
373 *freshwater rainbow trout aquaculture industry*.

374 Wahli, T., & Madsen, L. (2018). Flavobacteria, a never ending threat for fish: a review. *Current Clinical*  
375 *Microbiology Reports*, 5(1), 26–37. <https://doi.org/10.1007/s40588-018-0086-x>

376  
377  
378



379

380

381

382 **Table 1. Experimental design of vaccination trials.**

Degree days post-vaccination	Groups	No. Fish (replicate tanks)	Innoculum ( $\mu$ l i.p.)	Challenge strain i.m. (Dose:CFU/fish)
525	Control (unvaccinated)	15 (2)	50 $\mu$ l PBS	Homologous AVU-2T13 ( $1.3 \times 10^7$ )
	Vaccine + Montanide	15 (2)	50 $\mu$ l FKC:Montanide	Homologous AVU-2T13 ( $1.3 \times 10^7$ )
	Control (unvaccinated)	15 (2)	50 $\mu$ l PBS	Heterologous AVU-1T/07 ( $3.6 \times 10^7$ )
	Vaccine + Montanide	15 (2)	50 $\mu$ l FKC:Montanide	Heterologous AVU-1T/07 ( $3.6 \times 10^7$ )
1155	Control (unvaccinated)	14 (2)	50 $\mu$ l PBS	Heterologous AVU-1T/07 ( $1.7 \times 10^7$ )
	Vaccine (FKC)	14 (2)	50 $\mu$ l FKC	Heterologous AVU-1T/07 ( $1.7 \times 10^7$ )
	Vaccine & Montanide	14 (2)	50 $\mu$ l FKC:Montanide	Heterologous AVU-1T/07 ( $1.7 \times 10^7$ )

383

384 PBS: phosphate buffered saline; FKC: formalin-killed cells; i.p.: intra-peritoneal; i.m.: intra-muscular, CFU:

385 colony forming units

386

387

388

389

390

391

392

393

394

395

396

397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420

**Table 2. Agglutination titre of serum from trout unvaccinated (injected with PBS) and vaccinated (injected with FKC, or FKC emulsified with Montanide) at 1155 degree days post-vaccination.**

<b>Fish no.</b>	<b>Unvaccinated</b>	<b>FKC</b>	<b>FKC:Montanide</b>
<b>1</b>	<8	<8	128
<b>2</b>	<8	<8	64
<b>3</b>	<8	8	256
<b>4</b>	<8	<8	128

FKC: formalin-killed cells

421 Figure 1. Percentage survival of rainbow trout vaccinated by intraperitoneal injection with *Flavobacterium*  
422 *psychrophilum*-formalin killed cells (FKC) adjuvanted with Montanide ISA 760VG (FKC and Montanide) and  
423 challenged at 525 degree days post-vaccination (dd pv) by intramuscular injection with (A) a homologous strain  
424 of *F. psychrophilum* (RPS 76%); (B) a heterologous strain of *F. psychrophilum* (RPS 88%). Controls were given  
425 sterile phosphate buffered saline by intraperitoneal injection. The survival rates from each replicate tank  
426 following challenge are presented (n = 15; p = 0.0001).

427

428 Figure 2. Percentage survival of rainbow trout vaccinated by intraperitoneal injection with *Flavobacterium*  
429 *psychrophilum* formalin killed cells (FKC) with and without adjuvant (Montanide ISA 760VG) and challenged  
430 at 1155 degree days post vaccination (dd pv) by intramuscular injection with a heterologous strain of *F.*  
431 *psychrophilum*. FKC only (RPS 25%); FKC & Montanide (RPS 100%). Control fish received sterile phosphate  
432 buffered saline by intraperitoneal injection. The survival rates from each replicate tank following challenge are  
433 presented (n = 14; p = 0.0001).

434

435 Figure 3. Specific antibody (IgM) levels to *F. psychrophilum* in vaccinated rainbow trout at 1155 days post  
436 vaccination. (A) to homologous strain AVU-2T/13; (B) to homologous strain AVU-1T/13. Antibody levels were  
437 significantly higher in the fish vaccinated with adjuvant when compared with unvaccinated fish [AVU 1T/13 p =  
438 0.01, AVU 2T/13 p < 0.05]. Mean values are shown as blue dots. Groups that do not share a letter are  
439 significantly different, (n = 6).

440

441 Figure 4. SDS-PAGE of *Flavobacterim psychrophilum* strains. (a) Whole cell lysates from vaccine strains (Lane  
442 1: AVU-1T/13, Lane 2: AVU-2T/13, Lane 3: AVU-3S/13) and a heterologous strain (Lane 4: 171/07) were  
443 separated by SDS-PAGE and stained with Coomassie stain. Arrows indicate high intensity bands at 10-15, 20,  
444 37-50, 100 and 150-250 kDa. (b) Western blot analysis of a heterologous strain (Lane 1:171/07) and vaccine  
445 strains (Lane 2: AVU-1T/13, Lane 3: AVU-2T/13, Lane 4: AVU-3S/13). Whole cell lysates were separated by  
446 SDS-PAGE, blotted onto nitrocellulose and reacted with serum from (i) unvaccinated (control) fish, (ii) FKC  
447 vaccinated fish or (iii) FKC & Montanide vaccinated fish. Serum was a pool from two fish from each treatment  
448 group, with a titre of 512, taken 11 wpv. Arrows indicate high intensity bands between 20-25 kDa. Molecular  
449 mass standards (kDa) are indicated on the left.

450 Supplementary Figure 1. Nested PCR for detection of *F. psychrophilum* in colonies recovered from  
451 moribund/mortalities post-challenge. 1% agarose gel showing second round PCR products. M: Ladder, Lane1-  
452 16: bacterial DNA recovered from fish, (-) negative control, (+): positive control.  
453